Literature DB >> 30924397

Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings.

Staci Martin1, Marie Claire Roderick1, Cristina Abel1, Pamela Wolters1, Mary Anne Toledo-Tamula2, Courtney Fitzhugh3,4, Matthew Hsieh3, John Tisdale3.   

Abstract

Children and adults with sickle cell disease (SCD) are at risk for neuropsychological deficits; however, the neurocognitive functioning of adults with SCD and related comorbidities has not been widely reported in the literature. We examined specific cognitive domains in symptomatic adults with SCD and compared them with their unaffected siblings. We also examined relationships between cognitive scores, patient-reported outcomes (PROs), and medical/laboratory values. Thirty patient-sibling pairs (M patient age = 32.5 years, M sibling age = 32.1 years) completed evaluations as part of a medical clinical trial (NCT00061568). All patient and sibling neurocognitive test scores were within normal limits. Patients scored significantly lower (M = 91.0 ± 11.3) than their siblings (M = 100.6 ± 12.3; t = -3.5, p < .01) on the Wechsler Processing Speed Index. They also indicated more problems than siblings on an executive functioning questionnaire, although these differences were nonsignificant after accounting for depressive symptoms. Higher fetal hemoglobin and lower creatinine correlated with better scores on particular cognitive and PRO measures. In summary, our sample of adults with symptomatic SCD demonstrated worse processing speed and experience more executive challenges than their siblings, despite treatment with hydroxyurea. These relative weakness likely relate to disease processes but the specific physiological mechanism is unclear.

Entities:  

Keywords:  Neurocognitive functioning; Processing speed; Sibling controls; Sickle cell disease; Sickle cell trait

Mesh:

Substances:

Year:  2019        PMID: 30924397     DOI: 10.1080/09602011.2019.1598876

Source DB:  PubMed          Journal:  Neuropsychol Rehabil        ISSN: 0960-2011            Impact factor:   2.868


  4 in total

1.  Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait.

Authors:  Isabel V Lake; Jake A Ruddy; James A Saba; Sajya M Singh; Macy L Early; Rachel J Strodel; Sophie Lanzkron; Jennifer W Mack; Emily R Meier; Mindy S Christianson; Lydia H Pecker
Journal:  J Assist Reprod Genet       Date:  2021-11-22       Impact factor: 3.412

2.  Comprehensive assessment of cognitive function in adults with moderate and severe sickle cell disease.

Authors:  Gerard T Portela; Meryl A Butters; Maria M Brooks; Leticia Candra; Caterina Rosano; Enrico M Novelli
Journal:  Am J Hematol       Date:  2022-07-01       Impact factor: 13.265

3.  Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.

Authors:  Marsha J Treadwell; Lisa Du; Neha Bhasin; Anne M Marsh; Theodore Wun; M A Bender; Trisha E Wong; Nicole Crook; Jong H Chung; Shannon Norman; Nicolas Camilo; Judith Cavazos; Diane Nugent
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772

4.  Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.

Authors:  Andrew M Heitzer; Jennifer Longoria; Victoria Okhomina; Winfred C Wang; Darcy Raches; Brian Potter; Lisa M Jacola; Jerlym Porter; Jane E Schreiber; Allison A King; Guolian Kang; Jane S Hankins
Journal:  Br J Haematol       Date:  2021-07-16       Impact factor: 8.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.